scholarly journals Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up

Diagnostics ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 2316
Author(s):  
Suguru Ikeda ◽  
Takaaki Sugihara ◽  
Takuya Kihara ◽  
Yukako Matsuki ◽  
Takakazu Nagahara ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Serum Triglyceride ◽  
Gamma Glutamyl Transferase ◽  
Alcoholic Fatty Liver ◽  
Clinical Criteria ◽  
One Year ◽  
Glutamyl Transferase ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease related to metabolic syndrome. No standard pharmacological treatment has yet been established. We retrospectively evaluated the efficacy of pemafibrate in 16 NAFLD patients (11 men and 5 women; median age, 59 years; range, 27–81 years) who had taken pemafibrate for at least one year. They were all diagnosed with fatty liver according to imaging and clinical criteria. They were administered pemafibrate from October 2018 to October 2021 (median, 94 weeks; range, 56–157 weeks). Serum triglyceride was significantly decreased by −41.9% (342.3 ± 54.0 to 198.9 ± 20.4 mg/dL, p < 0.001). Aspartate aminotransferase (AST), alanine aminotransferase, and gamma-glutamyl transferase levels significantly decreased by −42.1% (49.6 ± 7.0 to 28.7 ± 3.4 U/L, p < 0.001), −57.1% (65.1 ± 10.8 to 27.9 ± 3.7 U/L, p < 0.001), and −43.2% (68.9 ± 10.9 to 39.1 ± 5.3 U/L, p < 0.05), respectively. The AST to platelet ratio (APRI) (0.8 ± 0.1 to 0.4 ± 0.1, p < 0.001) and fibrosis based on four factors (FIB-4) index (1.8 ± 0.3 to 1.4 ± 0.2, p < 0.05) also significantly decreased. Liver attenuation (39.1 ± 1.2 to 57.8 ± 2.7 HU, p = 0.028) and liver/spleen ratio (0.76 ± 0.04 to 1.18 ± 0.02, p = 0.012) significantly improved in three patients, as assessed by computed tomography. In conclusion, pemafibrate significantly improves serum triglyceride levels, liver function, FIB-4 index, APRI, and fatty liver in NAFLD patients with hypertriglyceridemia.

scholarly journals Biochemical Scoring System For Diagnosing Nonalcoholic steatohepatitis

2019 ◽  
Vol 30 (2) ◽  
pp. 58-62
Author(s):  
Sheikh Mohammad Noor E Alam ◽  
Shahinul Alam ◽  
Dulal Chandra Das ◽  
Mamun Al Mahtab
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Scoring System ◽  
Fatty Liver Disease ◽  
Serum Triglyceride ◽  
Gamma Glutamyl Transferase ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Glutamyl Transferase

Background: Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions ranging from simple steatosis to steatohepatitis, advanced fibrosis, and end stage liver disease. Despite the high prevalence and severity of hepatic illness, NAFLD remains underdiagnosed, because of few symptoms, lack of accurate laboratory markers. Objective: To evaluate a biochemical score for diagnosing non-alcoholic steatohepatitis. Methods: An observational, cross sectional study was carried out for a period of two years in the Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. 43 patients of Non-alcoholic fatty liver disease (NAFLD) attending at department of Hepatology were selected and underwent for biochemical investigations and liver biopsy with NAFLD Activity Score (NAS). Results: A biochemical score (TAAG score) assigned 1 point for each parameter (fasting serum triglyceride >ULN, alanine aminotransferase >ULN, AST/ALT ratio (AAR) ≤1 and gamma-glutamyl transferase >ULN) was evaluated. TAAG score ≥3 was present in 32.5% of study population and 40% of NASH patients. It had a sensitivity of 40%, specificity 26% and AUROC 0.54. Conclusion: Biochemical scoring system comprising traditional biomarkers did not significantly predict NASH. Biopsy is the only way to estimate steatohepatitis and/or fibrosis. Bangladesh J Medicine July 2019; 30(2) : 58-62

scholarly journals Non-Alcoholic Fatty Liver Disease Modifies Serum Gamma-Glutamyl Transferase in Cigarette Smokers

2020 ◽  
Vol 12 (8) ◽  
pp. 472-482
Author(s):  
Ebenezer T. Oni ◽  
Vincent Figueredo ◽  
Ehimen Aneni ◽  
Emir Veladar ◽  
John W. McEvoy ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Gamma Glutamyl Transferase ◽  
Cigarette Smokers ◽  
Alcoholic Fatty Liver ◽  
Gamma Glutamyl ◽  
Glutamyl Transferase ◽  
Alcoholic Fatty Liver Disease

scholarly journals Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhangya He ◽  
Xiaomin Li ◽  
Hexiang Yang ◽  
Pei Wu ◽  
Shanshan Wang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Glucose Metabolism ◽  
Vitamin C ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Hmw Adiponectin ◽  
Liver Health ◽  
Glutamyl Transferase ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is now recognized as the most prevalent hepatic disorder worldwide, and an unhealthy lifestyle is the leading risk factor for its occurrence. Vitamin C (VC) has been suggested to protect NAFLD, whereas evidence from randomized controlled trials (RCTs) is sparse. In this study, we aimed to investigate the potential benefits of VC supplementation daily on liver health and associated parameters in patients with NAFLD. In this double-blind, RCT, 84 patients with NAFLD, aged 18–60 years old, were assigned to 12 weeks of oral treatment with either low (250 mg/day, n = 26), medium (1,000 mg/day, n = 30), or high (2,000 mg/day, n = 28) doses of VC supplements. After the intervention, the Medium group had a more significant decrease in aspartate aminotransferase [Medium, −5.00 (−10.25, −1.75) vs. High, −2.50 (−7.75, 0.00), P = 0.02] and alanine aminotransferase [Medium, −8.00 (−18.00, −1.75) vs. High, −3.50 (−13.75, 4.25), P = 0.05; Medium vs. Low, −3.00 (−9.00, 5.50), P = 0.031]. The levels of other indicators of liver health, such as gamma-glutamyl transferase, alkaline phosphatase, total bilirubin, and direct bilirubin were decreased after the intervention but comparable among the three groups and so did the parameters of glucose metabolism, such as fasting insulin, fasting glucose, and homeostasis model assessment for insulin resistance. The plasma level of VC in patients and total adiponectin and high molecular weight (HMW) adiponectin levels were also elevated but not in a dose-dependent manner. Meanwhile, analysis of fecal microbiota composition showed an increase in the alpha diversity (Abundance-based Coverage Estimator (ACE), Shannon, chao1, and Simpson) both in the Low and the Medium groups. A total of 12 weeks of VC supplementation, especially 1,000 mg/day, improved liver health and glucose metabolism in patients with NAFLD. The elevated plasma levels of VC, total and HMW adiponectin, and the improvement of intestinal microbiota may have made some contributions.

A Correlation Study Between Non-alcoholic Fatty Liver Disease and Serum Triglyceride Level After an Oral Fat Tolerance Test

2021 ◽  
Author(s):  
Xiaoyu Hou ◽  
Yunpeng Guan ◽  
Yong Tang ◽  
An Song ◽  
Jiajun Zhao ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Serum Triglyceride ◽  
Serum Triglyceride Level ◽  
Peak Time ◽  
Alcoholic Fatty Liver ◽  
Postprandial Triglyceride ◽  
Healthy Participants ◽  
Alcoholic Fatty Liver Disease

Abstract Background: Non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases worldwide. High postprandial serum lipid concentrations have been reported in patients with metabolic syndrome. Meanwhile, postprandial triglyceride (TG) was found to be a potential replacement when fasting TG is not available. We aimed to investigate the relationship between postprandial TG concentration during oral fat tolerance testing (OFTT) and NAFLD. Methods : A total of 472 Chinese adults, aged 25 to 65 years enrolled in this study. All the participants underwent OFTT. Serum triglyceride and other lipid concentrations were measured, and their relationships with NAFLD were analyzed. Results: Of the 472 participants, 155 were diagnosed with NAFLD. The fasting and postprandial TG concentrations of the participants with NAFLD were higher than those of healthy participants (P<0.05). The TG concentrations of the healthy participants peaked 4 h postprandially, whereas those of the participants with NAFLD peaked 6 h postprandially and had higher peak values. Postprandial triglyceride concentration showed significant association with higher risk of NAFLD.Conclusions: Higher postprandial TG concentration is positively related to higher risk of NAFLD, and postprandial TG concnetrations of NAFLD patients were higher than healthy individuals with a delayed peak time. Hence, 4h postprandial TG maybe a potential indicator for NAFLD.Trial registration number: ChiCTR1800019514

DYSLIPIDEMIA IN NON ALCOHOLIC FATTY LIVER DISEASE

2021 ◽  
pp. 24-25
Author(s):  
Ruby Kumari ◽  
Prof. Santosh Kumar ◽  
Debarshi Jana
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Serum Triglyceride ◽  
Public Health Problem ◽  
P Value ◽  
Age Group ◽  
Alcoholic Fatty Liver ◽  
Current Scenario ◽  
Alcoholic Fatty Liver Disease

Background: NAFLD is a major alarming public health problem in current scenario. Still there is lack of wide research data in context of NAFLD, in our institute and state (Jharkhand) so we felt the need to do this research to assess dyslipidemia in cases of NAFLD. 100 Material and methods: patients (18-70 yrs) age Group, were included in the study. 50 diagnosed cases of Fatty Liver disease (FLD) by USG were enrolled in study. Subjects were divided in two equal groups, NAFLD and controls. Lipid prole was done in both groups. Data obtained during research was Result: statistically analyzed by using SPSS version 20. Student t test for independent samples was used to determine statistical signicance, p-value <0.05 was considered statistically signicant. serum Triglyceride, serum LDL-C and VLDL-C was signicantly raised and HDL-C signicantly decreased in NAFLD group compared to control. Dyslipidemia was obtained in NA Conclusion: FLD group.

scholarly journals Effects of coenzyme Q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with non-alcoholic fatty liver disease

2015 ◽  
Vol 11 (1) ◽  
pp. 35 ◽  
Author(s):  
Elnaz Jafarvand ◽  
Mahdieh Abbasalizad Farhangi ◽  
Beytollah Alipour ◽  
Manouchehr Khoshbaten
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Coenzyme Q10 ◽  
Fatty Liver Disease ◽  
Controlled Trial ◽  
Intervention Group ◽  
Serum Triglyceride ◽  
Dietary Factors ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

<p class="Abstract">This randomized double-blind placebo-controlled trial was conducted on 41 patients with non-alcoholic fatty liver disease. Patients in intervention group received 100 mg/day coenzyme Q10 (CoQ10) for four weeks. There was a significant reduction in waist circumference and aspartate aminotransferase concentrations after CoQ10 supplementation (p&lt;0.05). Dietary fiber was in negative correlation with change in serum alanine aminotransferase (ALT) concentrations (r = -410, p = 0.04), and dietary fat intake was in positive relation with serum triglyceride (r = 463, p = 0.04) and in negative relation with serum high-density lipoprotein cholesterol (HDL-C) (r = -533, p = 0.02) in CoQ10-treated group. CoQ10 supplement is able to reduce central obesity and improve liver function in non-alcoholic fatty liver disease. Dietary factors were also significant determinants of change in liver-specific enzyme ALT and lipid profile in these patients. Further trials with higher dose of CoQ10 and longer treatment periods are warranted to better clarify these findings.</p><p> </p>

Sign in / Sign up

Export Citation Format

Share Document